<DOC>
	<DOCNO>NCT01423084</DOCNO>
	<brief_summary>The primary objective study demonstrate equivalence rMenB+OMV NZ lot 1 rMenB+OMV NZ lot 2 administered adolescent , measure human serum bactericidal activity ( hSBA ) geometric mean titer ( GMTs ) 3 N. meningitidis serogroup B reference strain ( H44/76 , 5/99 , NZ98/254 ) measure ELISA geometric mean concentration ( GMCs ) vaccine antigen 287-953 , approximately 30 day primary vaccination course two dos administer one month apart .</brief_summary>
	<brief_title>Safety Immunogenicity Novartis Meningococcal B Vaccine Formulated With OMV Manufactured Two Different Sites , Healthy Adolescents Aged 11-17 Years</brief_title>
	<detailed_description>Novartis consider study success , one month follow second vaccination , two-sided 95 % CI ratio hSBA GMTs 3 serogroup B reference strain ( H44/76 , 5/99 , NZ98/254 ) two-sided 95 % CI ratio ELISA GMCs vaccine antigen 287-953 contain within interval ( 0.5 , 2.0 ) .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female subject ( 1117 year age inclusive ) give write assent whose parent legal guardian give write informed consent time enrollment available visit schedule study ( i.e. , plan leave area end study period ) good health determine outcome medical history , physical examination clinical judgment investigator . History serogroup B meningococcal vaccination Current previous , confirm suspected disease cause N. meningitidis Exposure individual laboratory confirm N. meningitidis infection within 60 day enrollment Significant acute chronic infection within previous 7 day fever ( defined axillary temperature ≥ 38.0 °C ) within previous day Antibiotic use within 3 day ( 72 hour ) prior enrollment Pregnancy nursing ( breastfeed ) mother Females childbearing age use plan use acceptable birth control measure , 2 month duration study . If sexually active subject must use one accepted birth control method least 30 day prior study entry Any serious chronic progressive disease , Known suspect impairment/alteration immune system Receipt blood , blood product and/or plasma derivative , parenteral immunoglobulin preparation within previous 90 day History severe allergic reaction previous vaccination hypersensitivity vaccine component</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Meningococcal Meningitis</keyword>
	<keyword>prevention , vaccination</keyword>
	<keyword>adolescent</keyword>
</DOC>